Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Human Mesenchymal Stem Cells Induce Liver Transplant Tolerance

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01690247
Recruitment Status : Unknown
Verified May 2013 by Fu-Sheng Wang, Beijing 302 Hospital.
Recruitment status was:  Recruiting
First Posted : September 21, 2012
Last Update Posted : May 31, 2013
Sponsor:
Information provided by (Responsible Party):
Fu-Sheng Wang, Beijing 302 Hospital

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Liver transplantation is the only lifesaving intervention for patients with end-stage liver diseases. Despite the ability of current immunosuppressive agents to reduce the incidence of acute rejection, the rate of acute rejection reaches to 20-50% after liver transplantation. Furthermore, the long-term toxicity associated with current regimens for liver transplant recipients now is increasingly being perceived as an unmet clinical need. Mesenchymal stem cells (MSC) appeared to be effective in regulating the invoked immune response in setting such as tissue injury, transplantation, and autoimmunity, and have been used successfully to treat graft versus host disease and show immune modulation function both in vitro and in vivo and may help in repairing damaged tissue(s). Here, we evaluate umbilical cord derived MSC (UC-MSC) as an alternative immunosuppressive agents for liver transplanted patients, and examine if UC-MSC could improve the recovery of liver function.

Condition or disease Intervention/treatment Phase
Evidence of Liver Transplantation Drug: Conventional plus UC-MSC Drug: Conventional plus placebo Phase 1

Detailed Description:

Liver transplantation is the only lifesaving intervention for patients with end-stage liver diseases. The current immunosuppressive agents reduce the incidence of acute cellular rejection; however, the rate of acute rejection reaches to 20-50% after liver transplantation. Furthermore, the long-term side effects of these regimens now has become a major challenge for liver transplant recipients and is increasingly being perceived as an unmet clinical need, for example, increases in the incidence of bacterial, viral infections, nephrotoxicity with chronic renal impairment, de novo diabetes mellitus, hyperlipidemia, arterial hypertension, cardiovascular disease, osteoporosis, neurotoxicity, hematological toxicity.

Mesenchymal stem cells (MSC) appeared to be effective in regulating the invoked immune response in setting such as tissue injury, transplantation, and autoimmunity, and have been used successfully to treat graft versus host disease and show immune modulation function both in vitro and in vivo and may help in repairing damaged tissue(s). Current clinical trails demonstrated that the use of autologous bone marrow MSC (BM-MSC) for renal transplanted patients resulted in lower incidence of acute rejection, decreased risk of opportunistic infection, and better estimated renal function. Compared with BM-MSC, umbilical cord derived MSC (UC-MSC) may be the better choice for clinical application. One main reason is that the collection of BM-MSC from liver transplanted patients would be harmful for the patients. Moreover, the proliferative abilities of BM-MSC from patients with liver disease are deficient, whereas, UC-MSC can be obtained from discarded umbilical cords and can be produced on a larger scale. Our and other studies reported that the infusion of human UC-MSC are feasible and can improve liver function of liver fibrosis and liver failure.

The purpose of this study is to learn whether and how UC-MSC can improve the conditions in liver transplanted patients. This study will also look at how well UC-MSC is tolerated and its safety in liver transplanted patients.

Participants in the study will be randomly assigned to one of two treatment arms:

Arm A: Participants will receive 12 weeks of standard regular immunosuppressive agents plus UC-MSC treatment. Arm B: Participants will receive 12 weeks of standard regular immunosuppressive agents plus placebo. UC-MSC will be prepared according to standard procedures and is collected in plastic bags containing anti coagulant. MSCs are given via i.v. under sonography monitoring. After UC-MSC transfusion, patients are followed up at week 4, 8, 12, 24, 36 and 48, and the evaluation of liver function recovery was performed.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Human Umbilical Cord Mesenchymal Stem Cell Induce Liver Allografts Tolerance
Study Start Date : February 2012
Estimated Primary Completion Date : February 2014
Estimated Study Completion Date : February 2015

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Conventional plus UC-MSC
Participants will receive conventional treatment plus a dose of UC-MSC from day 0 through the week 12 study visit. Participants will then be followed until the week 48 study visit
 Drug: Conventional plus UC-MSC
Received conventional treatment and taken i.v., once per 4 week, at a dose of 1×106 UC-MSC/kg body weight for 12 weeks.
Other Name: Immunosuppressive agents plus umbilical cord stem cells
Placebo Comparator: Conventional plus placebo
Participants will receive conventional plus placebo treatment from day 0 through the week 12 study visit. Participants will then be followed until the week 48 study visit.
 Drug: Conventional plus placebo
Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks.
Other Name: Immunosuppressive agents plus saline


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Incidence rate of acute rejection and early liver function recovery [ Time Frame: 48 weeks ]

Secondary Outcome Measures :
  1. Patient and graft survival, and prevalence of adverse events [ Time Frame: 48 weeks ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Written informed consent.
  2. Patients must be between the ages of 18 and 70 years and meet the criteria for liver transplantation.
  3. Patient is receiving the first liver transplant.
  4. Patient is receiving a liver transplant only.
  5. Negative pregnancy test (female patients in fertile age).
  6. Willing to comply with the study visits.

Exclusion Criteria:

  1. Previously received or is receiving an organ transplant other than a liver.
  2. Vital organs failure (Cardiac, Renal or Respiratory, et al).
  3. Currently receiving an investigational drug or received an investigational drug within 30 days prior to transplant.
  4. Currently receiving any immunosuppressive agent.
  5. Clinically active bacterial, fungal, viral or parasitic infection.
  6. Pregnant or lactating women.
  7. Other candidates who are judged to be not applicable to this study by investigators.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01690247


Contacts
Layout table for location contacts
Contact: Fu-Sheng Wang, PHD 86-10-63879735 ext 2015.12 fswang302@163.com
Contact: Ming Shi, PHD 86-10-63879735 ext 2015.12 shiming302@sina.com

Locations
Layout table for location information
China
Beijing 302 Hospital Recruiting
Beijing, China, 100039
Contact: Fu-Sheng Wang, PHD    86-10-63879735 ext 2015.12    fswang302@163.com   
Contact: Ming Shi, PHD    86-10-63879735 ext 2015.12    shiming302@sina.com   
Principal Investigator: Fu-Sheng Wang, PHD         
Sub-Investigator: Zhenwen Liu, Doctor         
Sub-Investigator: Ming Shi, PHD         
Sponsors and Collaborators
Beijing 302 Hospital
Investigators
Layout table for investigator information
Principal Investigator: Fu-Sheng Wang, PHD Beijing 302 Hospital
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications of Results:

Layout table for additonal information
Responsible Party: Fu-Sheng Wang, Research Center for Biotherapy, Beijing 302 Hospital
ClinicalTrials.gov Identifier: NCT01690247    
Other Study ID Numbers: Beijing302-008
First Posted: September 21, 2012    Key Record Dates
Last Update Posted: May 31, 2013
Last Verified: May 2013
Keywords provided by Fu-Sheng Wang, Beijing 302 Hospital:
mesenchymal stem cells
liver transplantation
clinical trial
rejection
Additional relevant MeSH terms:
Layout table for MeSH terms
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs